Top-News
Pharmazeutika USA

Blueprint Medicines News

Aktie
WKN:  A14SDD ISIN:  US09627Y1091 US-Symbol:  BPMC
95,76 €
-3,22 €
-3,25%
17.05.24 21:59:25
Handeln Depot/Watchlist
Aktienanzahl *
60,79 Mio.
Marktkapitalisierung *
5,87 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 16.01.2024

Blueprint Medicines News

16.05.24 - Der Aktionär
AKTIONÄR‑Depotwert Blueprint Medicines: "Best Idea" – neue Kaufempfehlung!
06.05.24 - PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
03.05.24 - Der Aktionär
AKTIONÄR‑Depotwert Blueprint Medicines wie entfesselt: Kursziele rauf
02.05.24 - Der Aktionär
AKTIONÄR‑Depotwert Blueprint Medicines erhöht Prognose – Aktie schießt hoch
02.05.24 - PR Newswire
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance PR Newswire
18.04.24 - PR Newswire
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 PR Newswire
11.04.24 - Der Aktionär
Blueprint Medicines: Das Multitalent
11.04.24 - PR Newswire
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-​Targeted Therapeutics PR Newswire
04.04.24 - PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
27.03.24 - Der Aktionär
AKTIONÄR‑Depotwert Blueprint Medicines mit Kaufsignal – die nächsten Ziele
06.03.24 - PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
29.02.24 - Der Aktionär
Blueprint Medicines: Zielgenaue Therapie
23.02.24 - PR Newswire
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire
16.02.24 - Der Aktionär
AKTIONÄR‑Hot‑Stock Blueprint Medicines: Top‑Prognose – Aktie gibt Vollgas
15.02.24 - PR Newswire
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results PR Newswire
05.02.24 - PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.02.24 - PR Newswire
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 PR Newswire
08.01.24 - PR Newswire
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
05.01.24 - PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
20.12.23 - Der Aktionär
AKTIONÄR‑Hot‑Stock Blueprint Medicines dreht weiter auf: Neue Kursziele!

Newssuche

Videos

newspaper
17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »